STRO Live signaler | Maksimer profitt med Getagraph.com

KJøP 106758 min ago

@ $4.45

Utstedt: 14 feb 2024 @ 19:11

Avkastning: -23.16%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: -4.28 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	468 783
Gjennomsnittsvolum	994 533
Markedsverdi	263.07M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.910 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.920
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.79
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

Volum Korrelasjon

Lang: -0.47 (neutral)

Kort: -0.20 (neutral)

Signal:(20.299) Neutral

Sutro Biopharma Inc Korrelasjon

10 Mest positive korrelasjoner
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 Mest negative korrelasjoner
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sutro Biopharma Inc Korrelasjon - Valuta/Råvare

-0.73
( moderate negative )

-0.66
( moderate negative )

0.00
( neutral )

0.47
( neutral )

Sutro Biopharma Inc Økonomi

Annual	2023
Omsetning:	$153.73M
Bruttogevinst:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2023
Omsetning:	$153.73M
Bruttogevinst:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2022
Omsetning:	$67.77M
Bruttogevinst:	$59.48M (87.77 %)
EPS:	$-2.35

FY	2021
Omsetning:	$61.88M
Bruttogevinst:	$61.88M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.